VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system
Collateral lethality occurs when loss of a gene/protein renders cancer cells dependent on its remaining paralog. Combining genome-scale CRISPR/Cas9 loss-of-function screens with RNA sequencing in over 900 cancer cell lines, we found that cancers of nervous system lineage, including adult and pediatr...
Main Authors: | Jonathan So, Nathaniel W. Mabe, Bernhard Englinger, Kin-Hoe Chow, Sydney M. Moyer, Smitha Yerrum, Maria C. Trissal, Joana G. Marques, Jason J. Kwon, Brian Shim, Sangita Pal, Eshini Panditharatna, Thomas Quinn, Daniel A. Schaefer, Daeun Jeong, David L. Mayhew, Justin Hwang, Rameen Beroukhim, Keith L. Ligon, Kimberly Stegmaier, Mariella G. Filbin, William C. Hahn |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2022-10-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.158755 |
Similar Items
-
Differential inhibitor sensitivity between human kinases VRK1 and VRK2.
by: Marta Vázquez-Cedeira, et al.
Published: (2011-01-01) -
VRK1 Kinase Activity Modulating Histone H4K16 Acetylation Inhibited by SIRT2 and VRK-IN-1
by: Eva Monte-Serrano, et al.
Published: (2023-03-01) -
The C/H3 domain of p300 is required to protect VRK1 and VRK2 from their downregulation induced by p53.
by: Alberto Valbuena, et al.
Published: (2008-01-01) -
Data on the identification of VRK2 as a mediator of PD-1 function
by: Michael Peled, et al.
Published: (2021-08-01) -
Effects of VRK2 (rs2312147) on white matter connectivity in patients with schizophrenia.
by: Hoyoung Sohn, et al.
Published: (2014-01-01)